{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:07:39Z","timestamp":1783548459156,"version":"3.55.0"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Locemia Solutions, Montreal, QC, Canada"},{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>In the present multicentre, open\u2010label, prospective, phase III study, we evaluated the real\u2010world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate\/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate\/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3\u2010mg dose of NG demonstrated real\u2010life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use.<\/jats:p>","DOI":"10.1111\/dom.13278","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T08:14:38Z","timestamp":1520237678000},"page":"1316-1320","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real\u2010world setting"],"prefix":"10.1111","volume":"20","author":[{"given":"Elizabeth R.","family":"Seaquist","sequence":"first","affiliation":[{"name":"University of Minnesota  Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Dulude","sequence":"additional","affiliation":[{"name":"Locemia Solutions  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-9128","authenticated-orcid":false,"given":"Xiaotian M.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Development, Diabetes Business Unit Eli Lilly Canada Inc  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Rabasa\u2010Lhoret","sequence":"additional","affiliation":[{"name":"Montreal Clinical Research Institute  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Tsoukas","sequence":"additional","affiliation":[{"name":"McGill University Health Center  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Conway","sequence":"additional","affiliation":[{"name":"Canadian Centre for Research on Diabetes  Smiths Falls Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Weisnagel","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec\u2010Universit\u00e9 Laval  Quebec City Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Gerety","sequence":"additional","affiliation":[{"name":"Division of Community Endocrinology Albany Medical College  Albany New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Woo","sequence":"additional","affiliation":[{"name":"University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Statistics Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolor\u00e8s","family":"Carballo","sequence":"additional","affiliation":[{"name":"Locemia Solutions  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Global Scientific Communications, Diabetes Business Unit Eli Lilly Services India Pvt. Ltd  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude A.","family":"Pich\u00e9","sequence":"additional","affiliation":[{"name":"Locemia Solutions  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-9463","authenticated-orcid":false,"given":"Cristina B.","family":"Guzman","sequence":"additional","affiliation":[{"name":"Medical Development, Diabetes Business Unit Formerly Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296814557518"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0103"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02867.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1498"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S20633"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.4.517"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1606"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0468"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204942"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2215"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1741"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0460"},{"key":"e_1_2_6_15_1","article-title":"A phase 3 multicenter, open\u2010label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting","author":"Deeb LC","year":"2018","journal-title":"Pediatr Diabetes"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:10Z","timestamp":1761870370000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/dom.13278"],"URL":"https:\/\/doi.org\/10.1111\/dom.13278","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"2017-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}